You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 3, 2024

Dextroamphetamine - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for dextroamphetamine and what is the scope of patent protection?

Dextroamphetamine is the generic ingredient in seven branded drugs marketed by Noven Pharms Inc, Impax Labs Inc, Able, Actavis Elizabeth, Dr Reddys Labs Sa, Nesher Pharms, Norvium Bioscience, Specgx Llc, Strides Pharma, Teva, Glaxosmithkline, Prasco, Tris Pharma Inc, Ani Pharms, Aurolife Pharma Llc, Avanthi Inc, Azurity, Barr, Epic Pharma Llc, Halsey, Lannett, Mast Mm, Novel Labs Inc, Nuvo Pharm, Purepac Pharm, Sandoz, Vitarine, Winder Labs Llc, Shire, and Ferndale Labs, and is included in forty-one NDAs. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Dextroamphetamine has thirty-three patent family members in twelve countries.

There are eighteen drug master file entries for dextroamphetamine. One supplier is listed for this compound. There is one tentative approval for this compound.

Drug Prices for dextroamphetamine

See drug prices for dextroamphetamine

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for dextroamphetamine
Generic Entry Date for dextroamphetamine*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT
Dosage:
SYSTEM;TRANSDERMAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for dextroamphetamine

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
The Beckwith InstitutePhase 4
Eva SzigethyPhase 4
Vallon Pharmaceuticals, Inc.Phase 1

See all dextroamphetamine clinical trials

Generic filers with tentative approvals for DEXTROAMPHETAMINE
Applicant Application No. Strength Dosage Form
⤷  Sign Up⤷  Sign Up30MGCAPSULE, EXTENDED RELEASE;ORAL
⤷  Sign Up⤷  Sign Up25MGCAPSULE, EXTENDED RELEASE;ORAL
⤷  Sign Up⤷  Sign Up20MGCAPSULE, EXTENDED RELEASE;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for dextroamphetamine

US Patents and Regulatory Information for dextroamphetamine

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Strides Pharma DEXTROAMPHETAMINE SULFATE dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 205077-001 Jun 21, 2019 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Norvium Bioscience DEXTROAMPHETAMINE SULFATE dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 206735-003 Jan 27, 2016 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Impax Labs Inc DEXEDRINE SPANSULE dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 017078-001 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for dextroamphetamine

Country Patent Number Title Estimated Expiration
Taiwan 200628175 Transdermal drug delivert device including an occlusive backing ⤷  Sign Up
Japan 2015535253 アンフェタミンの組成物及びアンフェタミンを経皮送達する方法 ⤷  Sign Up
World Intellectual Property Organization (WIPO) 2014066585 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.